Business Wire

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results | Business Wire

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout ...
Forbes

Why C-Band Is The 'It' Frequency Of 2022

There have been many FCC spectrum auctions over the last couple of years to aid in 5G network development, but none with as much lasting impact on the ecosystem as C-band. At the major auction last ...
Nasdaq

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that ...
Business Wire

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results Q1 2023 Readout Planned for FX-322-208 Phase 2b Sensorineural Hearing Loss Study, with Enrollment Completion ...
Nasdaq

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providing Runway ...